ZB-106-HS-202 Enrolling

Research Trial for Hidradenitis Suppurativa (44 Weeks)


Treatment: Injection Age: 18 Years


Who Can Participate?

Adults aged 18 to 70 years with hidradenitis suppurativa (HS), may be eligible.

 

Inclusion Criteria:

      • At least a 6-month history of HS
      • Have at least 5 painful lumps under the skin (abscess and/or inflammatory nodules) affecting at least 2 different body areas
      • An inadequate response to oral antibiotics for the treatment of HS

 

Participant Info:

      • No cost to participate or receive study treatment
      • Regular visits with study doctors who are familiar with hidradenitis suppurativa
      • Will receive investigational injected medication (active study drug) or placebo
      • Reimbursement for study-related expenses may be provided

 

How Long Will The Study Last?

Participation will last about 44 weeks and involve about 13 visits to the study research site


Participating Locations

COUNTRY
country-icon
Canada

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: August 12, 2025

Official Title

A Phase 2, Multi-Center Study Consisting of a Randomized, Placebo-Controlled Period, Followed by an Open-Label Extension Period to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults With Hidradenitis Suppurativa

ClinicalTrials.gov ID

NCT06993610

Sponsor

Zura Bio Inc

Study Description

  • Brief Summary:

    The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

  • Condition or Disease:

    Hidradenitis Suppurativa (HS)

  • Intervention/Treatment:

    Biological: Tibulizumab Dose A Biological: Tibulizumab Dose B Other: Placebo
  • Phase:

    PHASE 2

  • Ages Eligible for Study:

    18 Years and 70 Years (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Hidradenitis Suppurativa

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content